News

Inivata Announces Collaboration with Maverick Therapeutics for use of RaDaR™ Assay

RaDaR ctDNA liquid biopsy test to be used to monitor patient response in Phase 1/2 study of MVC-101 in multiple tumor types

Research Triangle Park, NC, USA and Cambridge, UK, 29 October 2020 – Inivata, a leader in liquid biopsy, today announces a collaboration with Maverick Therapeutics (“Maverick”) for the use of Inivata’s RaDaR™ assay for the detection and monitoring of residual disease and recurrence. RaDaR will be used to monitor circulating tumor DNA (ctDNA) in patients enrolled in the Phase 1/2 study of MVC-101, Maverick’s lead program candidate.

7th Crystal Structure Prediction Blind Test brings new challenges for computational chemists

• Announcing the challenge

This week the 7th CSP Blind Test begins - a major challenge in computational chemistry. It will see the world leading methods in Crystal Structure Prediction put to the test on real targets - with a high bar set by previous work. The 7 test systems have been sourced from leading experimentalists in industry and academia for prediction.

• The importance of CSP

The 3D structure and packing of crystalline materials have a big impact on their properties - this is most relevant in drug discovery and development.

AMSBIO announce a new rabbit and mouse recombinant monoclonal antibody development service based upon a revolutionary technology platform.

The DimAb™ development platform is different from traditional hybridoma fusion technologies in that it can directly isolate IgG genes from B cells of immunized animals. Using this novel platform - a number of custom development projects have already been completed with high customer satisfaction.

BioIVT to Host Emerging Technologies in Diagnostics Symposium

Westbury, NY – Oct. 26, 2020 – BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced that it will be hosting a virtual Emerging Technologies in Diagnostics Symposium from 10 a.m. to 1 p.m. ET on Thursday, Oct. 29.

Hikma and Arecor Expand Collaboration with New Agreement to Develop and Commercialise Ready-To-Administer Medicine

London and Cambridge, October 20, 2020 - Hikma Pharmaceuticals PLC (Hikma or the Group), the multinational pharmaceutical company, and Arecor Limited, the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announce they have entered into a new exclusive agreement to co-develop a ready-to-administer injectable medicine in the US through Hikma’s affiliate, Hikma Pharmaceuticals USA Inc. The agreement builds on Hikma and Arecor’s first product co-development agreement, which was announced on 9 January 2020.

BioIVT Launches HEPATOMUNE Kit to Facilitate Liver Toxicity and Inflammation Studies for Drug Discovery and Disease Research

Westbury, NY – Oct. 19, 2020 – BioIVT, a leading provider of research models and services for drug and diagnostic development, today launched its HEPATOMUNE® kit, a long-term, stable, in vitro model for evaluating immune-related and inflammation-mediated liver injury.

SARS-CoV-2 Antibodies and Antigens for Diagnostic Kit Development

AMSBIO has further expanded its product range to help in the fight against COVID-19 with the introduction of a new range of SARS-CoV-2 antibodies and antigens to aid development of new immunoassay diagnostic kits.

Study Shows Proof of Concept of BioIVT HEPATOPAC Cultures with Targeted Assay to Evaluate Bioactivation Potential and Drug-induced Liver Injury (DILI) Risk

New in vitro Bioactivation Liver Response Assay used HEPATOPAC model to demonstrate utility of in vitro transcriptomic signature-based strategy in preclinical DILI risk assessment

Westbury, NY – Oct. 12, 2020 – BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced the publication of research describing the use of HEPATOPAC® cultures with a targeted in vitro assay to identify small molecule drugs with high potential for drug-induced liver injury (DILI).¹

Stevenage Bioscience Catalyst opens Spark Building to support Cell and Gene scale-up

Stevenage Bioscience Catalyst’s new Spark Building opened its doors in January to accommodate the rapid growth of scale-up businesses within Hertfordshire’s world-class cell and gene cluster.

Mogrify introduces EpiMOGRIFY platform to systematically identify epigenetic switches driving cell identity and cell maintenance

Systematic direct cell conversion platform published in Cell Systems

Platform measures changes in H3K4me3 histone modifications to predict optimal growth factors required to both maintain cells in culture and support conversion between cell types

EpiMOGRIFY co-developed and co-owned by Duke-NUS, Monash University and Mogrify

My Account